Comparison of Decitabine with Venetoclax versus Intensive Chemotherapy Using Propensity Score Matching and Treatment-related Mortality Risk Scoring

Authors:

Abhishek Maiti,¹ Courtney D. DiNardo,¹ Farhad Ravandi,¹ Tapan M. Kadia,¹ Elias J. Jabbour,¹ Naval G. Daver,¹ Gautam Borthakur,¹ Guillermo Garcia-Manero,¹ Wei Qiao,⁴ Sherry A. Pierce,¹ Naveen Pemmaraju,¹ Kiran Naqvi,¹ Maro Ohanian,¹ Nicholas J. Short,¹ Yesid Alvarado,¹ Koichi Takahashi,¹ Musa Yilmaz,¹ Nitin Jain,¹ Steven Kornblau,¹ Koji Sasaki,¹ Michael Andreeff,¹ Prithviraj Bose,¹ Alessandra Ferrajoli,¹ Ghayas C. Issa,¹ Lucia Masarova,¹ Philip A. Thompson,¹ Caitlin R. Rausch,³ Jing Ning,⁴ Hagop M. Kantarjian,^{1 *}Marina Y. Konopleva ¹

1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
2. Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
3. Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
4. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
*Correspondence to [email protected]

Disclosure:

All of the following disclosures are outside of the submitted work. Dr Maiti has received research funding from Celgene. Dr Pemmaraju has received consultancy fees or honorarium from Celgene, Stemline, Incyte, Novartis, MustangBio, Roche Diagnostics, and LFB; research funding or clinical trials support from Stemline, Novartis, AbbVie, Samus, Cellectis, Plexxikon, Daiichi-Sankyo, and Affymetrix; and grants or funding from Affymetrix and the SagerStrong Foundation. Dr Daver has received consultancy fees from Sunesis Pharmaceuticals, Karyopharm, Pfizer, Bristol-Myers Squibb, Novartis, Otsuka America Pharmaceutical, Inc., and Jazz Pharmaceuticals; research funding from Sunesis Pharmaceuticals, Karyopharm, Immunogen, Pfizer, Incyte, Bristol-Myers Squibb, Daiichi-Sankyo, and Kiromi; and honoraria from Incyte. Dr Ravandi has received research funding from Amgen, Bristol-Myers Squibb, Merck, Seattle Genetics, and Sunesis Pharmaceuticals; honoraria from Amgen, Pfizer, Seattle Genetics, and Sunesis Pharmaceuticals; and had a consulting or advisory role for Amgen, Seattle Genetics, and Sunesis Pharmaceuticals. Dr Borthakur has received research funding from AbbVie, Incyte, Janssen, GlaxoSmithKline, Cyclacel, BioLine Rx, and Oncoceutics, Inc; and consultancy fees from BioLine Rx, NKarta, and PTC Therapeutics. Dr Short has received research funding from Takeda Oncology; consultancy fees from Takeda Oncology and AstraZeneca; and honoraria from Amgen. Dr Alvarado has received research funding from Jazz Pharmaceuticals; and honoraria from Abbott. Dr Takahashi has received consultancy fees from Symbio Pharmaceuticals. Dr Jain has received consultancy fees from AbbVie, Pharmacyclics, an AbbVie company, Janssen, Genentech, Pfizer, ADC Therapeutics, AstraZeneca, Servier, Verastem, Precision Biosciences, and Adaptive Biotechnologies; research funding from AbbVie, Pharmacyclics, an AbbVie company, Genentech, BMS, Pfizer, ADC Therapeutics, Incyte, AstraZeneca, Servier, Cellectis, Verastem, Precision Biosciences, and Adaptive Biotechnologies; honoraria from and held membership on an entity’s Board of Directors or advisory committees at AbbVie, Pharmacyclics, an AbbVie company, Janssen, Genentech, Pfizer, ADC Therapeutics, AstraZeneca, Servier, Verastem, Precision Biosciences, and Adaptive Biotechnologiess. Dr Sasaki has received consultancy fees from Pfizer; and honoraria from Otsuka. Dr Andreeff has received consultancy fees from Daiichi Sankyo, Jazz Pharmaceuticals, Celgene, Amgen, AstaZeneca, and 6 Dimensions Capital; patents and royalties, with patents licensed and royalty bearing from Daiichi Sankyo; research funding from Daiichi Sankyo, Breast Cancer Research Foundation, CPRIT, and NIH/NCI; equity ownership from Reata, Aptose, Eutropics, Senti Bio, Oncoceutics, and Oncolyze; and membership on an entity’s Board of Directors or advisory committees at Senti Bio, Center for Drug Research & Development, Cancer UK, NCI-CTEP, German Research Council, Leukemia Lymphoma Society, NCI-RDCRN (Rare Disease Clinical Research Network), CLL Foundation, and BiolineRx. Dr Bose has received consultancy fees from Incyte, Celgene, and Blueprint Medicines; research funding from Incyte, Celgene, Blueprint Medicines, Kartos Therapeutics, Constellation Pharmaceuticals, Pfizer, Astellas, NS Pharma, Promedior, and CTI BioPharma; and speakers bureau involvement at Incyte. Dr Jabbour has received consultancy fees and research funding from Takeda, BMS, Adaptive, Amgen, AbbVie, Pfizer, and Cyclacel LTD. Dr DiNardo has received honoraria from AbbVie, Agios, Novartis, Celgene, Daiichi-Sankyo, Jazz Pharmaceuticals, and Notable Laboratories; research funding from AbbVie, Agios, Novartis, Celgene, Daiichi-Sankyo, and Calithera Biosciences; and has had a role as a scientific advisory board member at Notable Laboratories.  Dr Kantarjian has received research funding from Ariad, Astex, BMS, Cyclacel, Daiichi-Sankyo, Pfizer, Immunogen, Jazz Pharmaceuticals, and Novartis; and honoraria from Pfizer, Immunogen, Actinium, and Takeda. Dr Konopleva has received research funding from Calithera, Stemline, Eli Lilly, AbbVie, Cellectis, F. Hoffman La-Roche, Genentech, Ascentage, Ablynx, AstraZeneca, and Agios; consultancy fees from Stemline, Forty-Seven, AbbVie, Amgen, F. Hoffman La-Roche, and Kisoji; honoraria from Stemline, Forty-Seven, AbbVie, Amgen, F. Hoffman La-Roche, Genentech, and Kisoji; equity ownership, patents, and royalties from Reata.

Acknowledgements:

The authors would like to thank all the patients and their caregivers, co-investigators, collaborators, and members of the study teams involved in these trials.

Citation:

EMJ Hematol. 2020;8[1]:67-70. Abstract Review No: AR7.

Keywords:

10 day, acute myeloid leukemia (AML), decitabine, treatment-related mortality, venetoclax.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.